CytokineticsCYTK
Recorded

Cytokinetics UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration32 minParticipants5

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Ash VermaAnalyst

All right, great. Good day, everybody. Next session here at UBS Biopharma Conference is Cytokinetics. Very excited to have the whole team here. Just quickly, Robert, thank you so much for joining us. Fady, Andrew, and Sung, this is really amazing. Thanks for joining our conference. Maybe, Robert, if you can give us a brief outline of what are some of the highlights coming out of third quarter earnings. I think people know the story very well, but just if you can hit on some of the key points that you outline.

Robert BlumPresident and CEO

Sure. Coming out of Q3 earnings, we feel like we're executing very, very well on our commercial launch of MYQORZO with focus to the U.S., but also with inclusion of Germany and soon other countries to follow. As it relates to the U.S., we believe we're delivering against all of the metrics and objectives, the KPIs that we laid out for the street earlier in the year. My colleagues can speak to them in detail. But as it relates to demonstrating that we are having effect to increase the prescribing of cardiac myosin inhibitors category growth at the same time we are climbing in preferential share of new scripts, we think we're demonstrating that MYQORZO, as differentiated, is meaningfully impacting the disease OHCM, but still with plenty of upside.

Robert BlumPresident and CEO

Even all together, BMS and Cytokinetics work now with CAMZYOS and MYQORZO respectively, we still have upwards of 80% of symptomatic diagnosed OHCM patients in the United States who are not receiving a cardiac myosin inhibitor. This morning, we announced that the U.S. FDA has approved our sNDA to be enabling of data from MAPLE-HCM to be included in an expanded label for MYQORZO. Why is that important? It's especially important because the bar was already very high. The data from SEQUOIA, the original pivotal study of MYQORZO, informed a label that included all patients with OHCM, with or without the beta blockers. One asks, why then submit the MAPLE data? FDA is now permitting of inclusion of MAPLE data as could be enabling of further differentiation for MYQORZO. MAPLE was a study of monotherapy aficamten versus monotherapy metoprolol.

Robert BlumPresident and CEO

Now we have in the label data to suggest why MYQORZO could be considered as an alternative to a beta blocker. Now, keep in mind, we believe, and as we've been guiding all along, we think this is incremental because the label already included all of OHCM. But for these data now in label, add to that our expectation that next year the guidelines may be updated to reflect MAPLE data and elevating aficamten in the step edit of patients around OHCM. We think this could be together transformative at that time. I think all of this combined underscores Cytokinetics is doing what it said it was going to do, executing well on the commercialization of MYQORZO, expanding the label to include MAPLE-HCM. Next up is, as we guided, submission of an sNDA inclusive of ACACIA data, and as that could be factoring into label next year.

Robert BlumPresident and CEO

So it is incumbent upon us to continue to pioneer and lead, and we think we are doing just that.

Ash VermaAnalyst

Great. Awesome. So yeah, thanks a lot for that, and yeah, and congrats on the first-line approval. Maybe I will start there. I think it is interesting that, so you mentioned that the guidelines could get updated next year, but the payers would still step edit through the beta blockers. I am surprised that there is so much resistance in the payer community. This is not a massive market, right? But when you think about that, the data that we have seen, beta blockers are actually hurting patients. So I have been just thinking, what is the argument that you hear from payers in terms of, let us say, not putting CMIs first line, for MYQORZO first line, given that we have seen such an amazing data, and if the guidelines also get updated, then what would be their response to not use it?

Robert BlumPresident and CEO

Like with anything else, there is inertia.

Robert BlumPresident and CEO

Right. Inertia gets chipped away with more and more evidence, more and more time.

Robert BlumPresident and CEO

So maybe Andrew could speak to payer feedback in connection with these matters, and then Fady could speak to physician behavior.

Andrew CallosEVP and Chief Commercial Officer

Yeah. I mean, payers are certainly leading on guidelines as kind of their argument for why have utilization criteria around trying a beta blocker first, or a physician attesting that a beta blocker has been tried or the patient can't take it. Payers, this category and all categories, typically will put up challenges to make sure that appropriate patients are taking therapies that are more costly than what physicians have used historically. I think it's probably in our best interest for now to more accelerate the addition of a CMI, as compared to take on payer as a try for monotherapy. If we did that, I think there'd be a lot more contracting, rebating, market access would be more challenging than it is as a category.

Andrew CallosEVP and Chief Commercial Officer

I think as Robert said, inertia, data, over time, especially if nHCM is approved, that guidelines get updated, you may see criteria loosened, but not in the next one, two years.

Fady MalikEVP of Research and Development

Yeah, I think to influence physician behavior, step one is to generate high-quality data. With MYQORZO, we now have SEQUOIA, we have MAPLE, we have ACACIA, FOREST data. The guidelines were written on expert opinion because there was no high-quality data for the use of beta blockers or everything else. That's not a position. I mean, they accommodate expert opinion because sometimes there's nothing else to fall back on, but the field is being transformed by now availability of high-quality, randomized controlled clinical data. They, I expect, will be updated to reflect that in the next version, which we expect in 2027. Guidelines then help influence physician behavior, because the guidelines are the ultimate kind of peer review, and your peers have now voted to position things a certain way. Physicians, I think they incorporate that into their practice as well.

Fady MalikEVP of Research and Development

Most of the truly expert physicians have moved, they're not waiting for the guidelines, they've already moved to implement.

Fady MalikEVP of Research and Development

Yeah in their practice that the data that have been presented and published now.

Robert BlumPresident and CEO

But I think the net of what you're hearing from Andrew and Fady is that payers will come along when they see physician behavior altering and the use of aficamten more frontline. In the meantime, physicians, knowing of this payer headwind, will likely be moving more swiftly through beta blockers, step edit through them more rapidly in order to be able to get their patients sooner on aficamten.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day